{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:54:45Z","timestamp":1772826885827,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00432-020-03458-6","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T18:03:27Z","timestamp":1605722607000},"page":"1803-1811","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California"],"prefix":"10.1007","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7060-5123","authenticated-orcid":false,"given":"Gino K.","family":"In","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poorva","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Filkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Hermel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin G.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Kokot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Menendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittney","family":"DeClerck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny C.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Terando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Jadvar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charit\u00e9","family":"Ricker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Wysong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"issue":"4","key":"3458_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372(4):311\u2013319. https:\/\/doi.org\/10.1056\/NEJMoa1411087","journal-title":"N Engl J Med"},{"issue":"1","key":"3458_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.clsc.2016.11.001","volume":"1","author":"JH Assam","year":"2016","unstructured":"Assam JH, Powell S, Spanos WC (2016) Unresectable cutaneous squamous cell carcinoma of the forehead with MLH1 mutation showing dramatic response to programmed cell death protein 1 inhibitor therapy. Clin Skin Cancer 1(1):26\u201329. https:\/\/doi.org\/10.1016\/j.clsc.2016.11.001","journal-title":"Clin Skin Cancer"},{"issue":"2","key":"3458_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"issue":"8","key":"3458_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/s1470-2045(08)70178-5","volume":"9","author":"KD Brantsch","year":"2008","unstructured":"Brantsch KD, Meisner C, Schonfisch B, Trilling B, Wehner-Caroli J, Rocken M et al (2008) Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 9(8):713\u2013720. https:\/\/doi.org\/10.1016\/s1470-2045(08)70178-5","journal-title":"Lancet Oncol"},{"issue":"8","key":"3458_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1610-0387.2012.07896.x","volume":"10","author":"H Breuninger","year":"2012","unstructured":"Breuninger H, Brantsch K, Eigentler T, Hafner HM (2012) Comparison and evaluation of the current staging of cutaneous carcinomas. J Dtsch Dermatol Ges 10(8):579\u2013586. https:\/\/doi.org\/10.1111\/j.1610-0387.2012.07896.x","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"3458_CR6","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1038\/s41598-019-39594-4","volume":"9","author":"YK Chae","year":"2019","unstructured":"Chae YK, Anker JF, Oh MS, Bais P, Namburi S, Agte S et al (2019) Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma. Sci Rep 9(1):3235. https:\/\/doi.org\/10.1038\/s41598-019-39594-4","journal-title":"Sci Rep"},{"issue":"10","key":"3458_CR7","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1084\/jem.20071190","volume":"205","author":"RA Clark","year":"2008","unstructured":"Clark RA, Huang SJ, Murphy GF, Mollet IG, Hijnen D, Muthukuru M et al (2008) Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 205(10):2221\u20132234. https:\/\/doi.org\/10.1084\/jem.20071190","journal-title":"J Exp Med"},{"issue":"6","key":"3458_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1159\/000461578","volume":"232","author":"O Dereure","year":"2016","unstructured":"Dereure O, Missan H, Girard C, Costes V, Guillot B (2016) Efficacy and tolerance of cetuximab alone or combined with chemotherapy in locally advanced or metastatic cutaneous squamous cell carcinoma: an open study of 14 patients. Dermatology 232(6):721\u2013730. https:\/\/doi.org\/10.1159\/000461578","journal-title":"Dermatology"},{"issue":"6","key":"3458_CR9","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.jaad.2010.08.033","volume":"64","author":"S Farasat","year":"2011","unstructured":"Farasat S, Yu SS, Neel VA, Nehal KS, Lardaro T, Mihm MC et al (2011) A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol 64(6):1051\u20131059. https:\/\/doi.org\/10.1016\/j.jaad.2010.08.033","journal-title":"J Am Acad Dermatol"},{"issue":"19","key":"3458_CR10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"issue":"10","key":"3458_CR11","doi-asserted-by":"publisher","first-page":"e110928","DOI":"10.1371\/journal.pone.0110928","volume":"9","author":"A Freeman","year":"2014","unstructured":"Freeman A, Bridge JA, Maruthayanar P, Overgaard NH, Jung JW, Simpson F et al (2014) Comparative immune phenotypic analysis of cutaneous squamous cell carcinoma and intraepidermal carcinoma in immune-competent individuals: proportional representation of CD8+ T-cells but not FoxP3+ regulatory T-cells is associated with disease stage. PLoS ONE 9(10):e110928. https:\/\/doi.org\/10.1371\/journal.pone.0110928","journal-title":"PLoS ONE"},{"issue":"4","key":"3458_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/jamadermatol.2013.2456","volume":"149","author":"A Jambusaria-Pahlajani","year":"2013","unstructured":"Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, Hwang WT, Gelfand JM, Whalen FM et al (2013) Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol 149(4):402\u2013410. https:\/\/doi.org\/10.1001\/jamadermatol.2013.2456","journal-title":"JAMA Dermatol"},{"issue":"6","key":"3458_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/coc.0000000000000088","volume":"39","author":"A Jarkowski 3rd","year":"2016","unstructured":"Jarkowski A 3rd, Hare R, Loud P, Skitzki JJ, Kane JM 3rd, May KS et al (2016) Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the roswell park experience and a review of the literature. Am J Clin Oncol 39(6):545\u2013548. https:\/\/doi.org\/10.1097\/coc.0000000000000088","journal-title":"Am J Clin Oncol"},{"issue":"10","key":"3458_CR14","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/s1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D\u2019Angelo SP et al (2016) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17(10):1374\u20131385. https:\/\/doi.org\/10.1016\/s1470-2045(16)30364-3","journal-title":"Lancet Oncol"},{"issue":"26","key":"3458_CR15","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509\u20132520. https:\/\/doi.org\/10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"issue":"6349","key":"3458_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409\u2013413. https:\/\/doi.org\/10.1126\/science.aan6733","journal-title":"Science"},{"issue":"6","key":"3458_CR17","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1158\/1078-0432.ccr-14-1773","volume":"21","author":"YY Li","year":"2015","unstructured":"Li YY, Hanna GJ, Laga AC, Haddad RI, Lorch JH, Hammerman PS (2015) Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res 21(6):1447\u20131456. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-1773","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3458_CR18","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","volume":"166","author":"A Lomas","year":"2012","unstructured":"Lomas A, Leonardi-Bee J, Bath-Hextall F (2012) A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 166(5):1069\u20131080. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10830.x","journal-title":"Br J Dermatol"},{"issue":"2","key":"3458_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3322\/caac.21389","volume":"67","author":"WM Lydiatt","year":"2017","unstructured":"Lydiatt WM, Patel SG, O\u2019Sullivan B, Brandwein MS, Ridge JA, Migliacci JC (2017) Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 67(2):122\u2013137","journal-title":"CA Cancer J Clin"},{"issue":"30","key":"3458_CR20","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1200\/jco.19.00318","volume":"37","author":"VE Maher","year":"2019","unstructured":"Maher VE, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M et al (2019) Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J Clin Oncol 37(30):2730\u20132737. https:\/\/doi.org\/10.1200\/jco.19.00318","journal-title":"J Clin Oncol"},{"issue":"25","key":"3458_CR21","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/jco.2010.34.1735","volume":"29","author":"E Maubec","year":"2011","unstructured":"Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J et al (2011) Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29(25):3419\u20133426. https:\/\/doi.org\/10.1200\/jco.2010.34.1735","journal-title":"J Clin Oncol"},{"key":"3458_CR22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131","author":"MR Migden","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD et al (2018) PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1805131","journal-title":"N Engl J Med"},{"issue":"2","key":"3458_CR23","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/s1470-2045(19)30728-4","volume":"21","author":"MR Migden","year":"2020","unstructured":"Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L et al (2020) Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 21(2):294\u2013305. https:\/\/doi.org\/10.1016\/s1470-2045(19)30728-4","journal-title":"Lancet Oncol"},{"issue":"19","key":"3458_CR24","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"issue":"26","key":"3458_CR25","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L et al (2016) PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N Engl J Med 374(26):2542\u20132552. https:\/\/doi.org\/10.1056\/NEJMoa1603702","journal-title":"N Engl J Med"},{"issue":"24","key":"3458_CR26","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1158\/1078-0432.ccr-14-1768","volume":"20","author":"CR Pickering","year":"2014","unstructured":"Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE et al (2014) Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 20(24):6582\u20136592. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-1768","journal-title":"Clin Cancer Res"},{"issue":"19","key":"3458_CR27","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"issue":"2","key":"3458_CR28","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/bjd.13741","volume":"173","author":"M Reigneau","year":"2015","unstructured":"Reigneau M, Robert C, Routier E, Mamelle G, Moya-Plana A, Tomasic G et al (2015) Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas. Br J Dermatol 173(2):527\u2013534. https:\/\/doi.org\/10.1111\/bjd.13741","journal-title":"Br J Dermatol"},{"issue":"4","key":"3458_CR29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"3458_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","volume":"109","author":"J Rogado","year":"2019","unstructured":"Rogado J, S\u00e1nchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Lev\u00ed A et al (2019) Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer 109:21\u201327. https:\/\/doi.org\/10.1016\/j.ejca.2018.10.014","journal-title":"Eur J Cancer"},{"issue":"10","key":"3458_CR31","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","volume":"151","author":"HW Rogers","year":"2015","unstructured":"Rogers HW, Weinstock MA, Feldman SR (2015) Incidence estimate of nonmelanoma skin cancer (Keratinocyte Carcinomas) in the US population, 212. JAMA Dermatol 151(10):1081\u20131086","journal-title":"JAMA Dermatol"},{"issue":"1","key":"3458_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jamadermatol.2013.6675","volume":"150","author":"AR Schmitt","year":"2014","unstructured":"Schmitt AR, Brewer JD, Bordeaux JS, Baum CL (2014) Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol 150(1):19\u201324. https:\/\/doi.org\/10.1001\/jamadermatol.2013.6675","journal-title":"JAMA Dermatol"},{"issue":"5","key":"3458_CR33","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamadermatol.2013.2139","volume":"149","author":"CD Schmults","year":"2013","unstructured":"Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA (2013) Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 149(5):541\u2013547. https:\/\/doi.org\/10.1001\/jamadermatol.2013.2139","journal-title":"JAMA Dermatol"},{"issue":"4","key":"3458_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamadermatol.2015.4994","volume":"152","author":"AK Thompson","year":"2016","unstructured":"Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL (2016) Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol 152(4):419\u2013428. https:\/\/doi.org\/10.1001\/jamadermatol.2015.4994","journal-title":"JAMA Dermatol"},{"issue":"2","key":"3458_CR35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/dss.0000000000001755","volume":"45","author":"C Trodello","year":"2019","unstructured":"Trodello C, Higgins S, Ahadiat O, Ragab O, In G, Hawkins M et al (2019) Cetuximab as a component of multimodality treatment of high-risk cutaneous squamous cell carcinoma: a retrospective analysis from a single tertiary academic medical center. Dermatol Surg 45(2):254\u2013267. https:\/\/doi.org\/10.1097\/dss.0000000000001755","journal-title":"Dermatol Surg"},{"issue":"9","key":"3458_CR36","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","volume":"5","author":"TS Uldrick","year":"2019","unstructured":"Uldrick TS, Gon\u00e7alves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS et al (2019) Assessment of the safety of pembrolizumab in patients with hiv and advanced cancer-a phase 1 study. JAMA Oncol 5(9):1332\u20131339. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2244","journal-title":"JAMA Oncol"},{"key":"3458_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.06.026","author":"P Vaidya","year":"2019","unstructured":"Vaidya P, Mehta A, Ragab O, Lin S (2019) Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma. JAAD Case Rep. https:\/\/doi.org\/10.1016\/j.jdcr.2019.06.026","journal-title":"JAAD Case Rep"},{"issue":"5","key":"3458_CR38","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00262-018-2138-8","volume":"67","author":"V Varki","year":"2018","unstructured":"Varki V, Ioffe OB, Bentzen SM, HeathJ CA, Feliciano J et al (2018) PD-L1, B7\u2013H3, and PD-1 expression in immunocompetent vs immunosuppressed patients with cutaneous squamous cell carcinoma. Cancer Immunol Immunother 67(5):805\u2013814. https:\/\/doi.org\/10.1007\/s00262-018-2138-8","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"3458_CR39","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/s1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375\u2013384. https:\/\/doi.org\/10.1016\/s1470-2045(15)70076-8","journal-title":"Lancet Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03458-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-020-03458-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03458-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T12:06:00Z","timestamp":1619438760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-020-03458-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["3458"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03458-6","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Gino K. In: advisory boards\/consulting for Sanofi, BMS, Novartis, Array, and Castle Biosciences; speaker for Merck; clinical trials\/research support from Genentech, Idera, and Regeneron. Julie E. Lang: speaker for Genomic Health; research support from ANGLE Parsortix. Jenny C. HU: advisory board for Regeneron. Ashley Wysong: research support from Castle Biosciences. All the other authors: no conflicts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed and approved by the institutional review board at the University of Southern California. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all the individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was obtained from all the individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request. All data and materials support the published claims and comply with field standards. This work has been partially presented in abstract form at the 2018 ASCO Annual Meeting. Otherwise, all the other content has not been published elsewhere, nor is under consideration for publication anywhere else.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}